Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
- Conditions
- Arthritis, RheumatoidGliomaBrain CancerCentral Nervous System Neoplasms
- Interventions
- Radiation: [18F]FHBG
- Registration Number
- NCT00185848
- Lead Sponsor
- Sanjiv Sam Gambhir
- Brief Summary
The purpose of this study is to determine whether \[18F\]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of \[18F\]FHBG in patients.
- Detailed Description
The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- Clinical diagnosis of brain tumor or rheumatoid arthritis
- Below 18 years of age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [18F]FHBG arm [18F]FHBG -
- Primary Outcome Measures
Name Time Method The primary endpoint of the study for each patient is acquisition of PET/CT image. Time of scan
- Secondary Outcome Measures
Name Time Method Collection of vital signs, EKG, blood chemistry and CBC data day 1, 2 and 8.
Trial Locations
- Locations (2)
University of California Los Angeles
🇺🇸Los Angeles, California, United States
Stanford University School of Medicine
🇺🇸Stanford, California, United States